No abstract available.
Animals ; Antibodies* ; Antibodies, Anticardiolipin ; beta 2-Glycoprotein I* ; Mice* ; T-Lymphocytes, Helper-Inducer*

To evaluate the data obtained from the external quality assurance program initiated by Chinese Rheumatism Data Center (CRDC-QAP) for autoantibodies detection in 2021, so as to assess the consensus and differences in cross-laboratory testing to autoantibodies in China. This is a retrospective study. After collecting data from the first half year (from May 15th to July 10th) and the second half year (from August 15th to November 19th) of CRDC-QAP program for autoantibody detection in 2021, it firstly analyzed the qualitative consensus of the cross-laboratory results. Secondly, it compared the positivity grade of numeric results according to the Sample to cut-off ratio (S/CO ratio) calculation. Finally, the mean and coefficient variation (<i>CVi>) of numeric results from three major manufacturers were calculated. A total of 303 and 332 clinical labs voluntarily participated in the first half year and the second half year of CRDC-QAP program for autoantibody detection in 2021, respectively. Except for anti-β2 glycoprotein type I (aβ2-GPI) IgM, the cross-laboratory consensus of qualitative results for the other autoantibodies is greater than 96%. As for anti-cyclic citrullinated peptide antibody (anti-CCP) and anti mitochondrial antibody-M2 (AMA-M2), the numeric results from more than 90% laboratories showed the same positivity grade. More than 50% of laboratories used chemiluminescence immunoassay (CLIA) for quantitative evaluation of autoantibody. The CV of numeric results from different manufacturers showed certain differences(<i>Pi><0.01) with the range from 0 to 238%. Although high consensus can be observed in term of qualitative result for autoantibody detection in cross-laboratory, there are still certain differences in numeric results in term of positivity grade and manufacturer-based CV.
Humans ; Autoantibodies ; Antibodies, Anticardiolipin/analysis* ; Retrospective Studies ; East Asian People ; beta 2-Glycoprotein I ; Rheumatic Diseases

Antibodies to cardiolipin and other phospholipid have been associated with recurrent thrombotic events, including ischemic strokes, especially in children and young adults. Recently it has been shown that anti-beta2-glycoprotein I antibodies may be more specific in predicting thrombosis. We report a case of anterior spinal artery syndrome with elevated titer of antibodies to beta2-glycoprotein I in young adult.
Anterior Spinal Artery Syndrome ; Antibodies ; Antiphospholipid Syndrome ; beta 2-Glycoprotein I ; Cardiolipins ; Child ; Humans ; Stroke ; Thrombosis ; Young Adult

BACKGROUND: The conventional anticardiolipin antibody (aCL)-ELISA test that has been widely used to diagnose antiphospholipid syndrome (APS) has drawbacks in that false-positive reactions can occur. There have been considerable controversy as to the exact nature of the epitopes to which antiphosholipid antibodies (a PL) are directed. Almost all investigators now agree that the actual antigen to which aPL derived from patient with APS is directed, is beta2-glycoprotein I (beta2GPI). Therefore, we thought that anti-beta2GPI antibodies (abeta2GPI) might be a more specific marker for APS, and attempted to evaluate the usefulness of abeta2GPI test. METHODS: ELISA tests for a CL-IgG and abeta2GPI-IgG were performed simultaneously using the sera from 70 patients with clinically suspected APS and 10 healthy volunteers. The results of abeta2GPI were compared with those of aCL and evaluated clinically by reviewing the medical records. RESULTS: The correlation coefficient between the two was 0.54 (p<0.005). Twelve of 70 patients were abeta2GPI-positive and they were also positive for aCL (mean 45GPL). Forty of 58 abeta2GPI- negative patients were aCL-positive, and many of them were diagnosed to have APS clinically. There was no case showing aCL-negative but abeta2GPI-positive result. CONCLUSIONS: According to our results, abeta2GPI test seems specific but too insensitive to differentiate APS by itself, so it has no additional diagnostic value superior to aCL test. We believe that a study which includes more cases and various test methods will be needed for the precise assessment of abeta2GPI test.
Antibodies ; Antibodies, Anticardiolipin ; Antiphospholipid Syndrome* ; beta 2-Glycoprotein I ; Diagnosis* ; Enzyme-Linked Immunosorbent Assay ; Epitopes ; Healthy Volunteers ; Humans ; Medical Records ; Research Personnel

Thrombosis is a well known manifestation in patients with systemic lupus erythematosus, along with lupus anticoagulant, anticardiolipin antibody and anti beta2-glycoprotein I. We describe here a 44-year-old female with an abdominal aorta thrombosis of SLE and the patient had no antiphospholipid antibodies. She had this unusual site of thrombosis and this was associated with protein C and S deficiency. She had no other cause of thrombosis. After anticoagulant treatment, her thrombosis of the abdominal aorta resolved.
Adult ; Antibodies, Anticardiolipin ; Antibodies, Antiphospholipid ; Aorta ; Aorta, Abdominal ; beta 2-Glycoprotein I ; Female ; Humans ; Lupus Coagulation Inhibitor ; Lupus Erythematosus, Systemic ; Protein C ; Thrombosis

OBJECTIVETo clarify the binding character between Beta-2-glycoprotein I (Beta-2-GPI) and HBsAg.

METHODSBeta-2-GPI was purified from human plasma and labelled with biotin. Solid phase enzyme linked absorbance assay was used to investigate its binding with HBsAg.

RESULTSBiotinylated Beta-2-GPI was found to bind HBsAg and the reaction could be inhibited by excess unlabelled Beta-2-GPI.

CONCLUSIONSBeta-2-GPI may play a role in hepatitis B virus infection.

Binding Sites ; Biotinylation ; Enzyme-Linked Immunosorbent Assay ; methods ; Glycoproteins ; isolation & purification ; metabolism ; Hepatitis B Surface Antigens ; metabolism ; Hepatitis B virus ; chemistry ; metabolism ; Humans ; beta 2-Glycoprotein I

OBJECTIVETo study the value of apolipoprotein H (apoH) gene expression in peripheral blood mononuclear cell (PBMC) and urinary N-Acetyl-beta-D-Glucosaminidase (NAG) and retinal-binding protein (RBP) in the early diagnosis of renal function damage in neonates.

METHODSSixty sick neonates who renal function damage probably occurred were enrolled. The blood and urinary samples were collected twice within 48 hrs following admission, with an interval of 12-24 hrs. Expression of apoH gene in PBMC was determined with RT-PCR. The levels of blood urea nitrogen (BUN) and creatinine, and urinary activities of NAG and RBP were measured with enzymatic reaction.

RESULTSThe abnormal rates of blood apoH and urinary NAG and RBP were 73.3%, 83.3% and 76.7%, respectively in the first detection. The second detection for blood apoH and urinary NAG and RBP showed abnormal rates of 70.0%, 66.7% and 76.7%, respectively. There were no significant differences in the abnormal rates between the three markers either in the first or the second detection (P>0.05). Beside there were no significant significances in the abnormal rates between urinary NAG and blood BUN in the second detection, the abnormal rates of blood apoH and urinary NAG and RBP in both detections were significantly higher than those of BUN or creatinine (P<0.01 or 0.05).

CONCLUSIONSThere are identical values of blood apoH gene expression and urinary NAG and RBP in the early diagnosis of renal function damage in neonates. The above three markers are more sensitive to early renal function damage than blood BUN and creatinine.

Acetylglucosaminidase ; urine ; Blood Urea Nitrogen ; Creatinine ; blood ; Female ; Humans ; Infant, Newborn ; Kidney Diseases ; diagnosis ; physiopathology ; Male ; Retinol-Binding Proteins ; urine ; beta 2-Glycoprotein I ; blood ; genetics

Antibodies, Anticardiolipin ; blood ; Autoantibodies ; blood ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Male ; Mucocutaneous Lymph Node Syndrome ; immunology ; beta 2-Glycoprotein I ; immunology

OBJECTIVETo further study the binding character of hepatitis B surface antigen (HBsAg) and beta 2-glycoprotein I (beta2GP I) and to explore whether beta2GP I plays an important role in the hepatotropism of hepatitis B virus.

METHODSUsing Western blot technique, we observed the binding character of the HBsAg with reduced and non-reduced beta2GP I.

RESULTSrHBsAgs with reduced and non-reduced beta2GP I showed identical binding activity.

CONCLUSIONSThe binding activity of HBsAg is dependent on tandem residues, but not on conformational structures of beta2GP I. There is a specific binding between HBV and beta2GP I, which may play an important role in HBV infection and is one of the reasons of hepatotropism of HBV.

Hepatitis B ; virology ; Hepatitis B Surface Antigens ; metabolism ; Hepatitis B virus ; pathogenicity ; Humans ; Viral Envelope Proteins ; blood ; beta 2-Glycoprotein I ; blood

OBJECTIVESTo study the interaction of beta-2-glycoprotein I (beta 2GPI) with the membrane of hepatocytes and determine whether beta 2GPI participates in HBV infection.

METHODSLigand blotting, fluorescence microscopy, and fluorescence activated cell sorter (FACS) analysis were used to detect the specific interaction of beta 2GPI with the hepatoma cell line smmc7721, the gastric carcinoma cell line SGC7901, and the lymphoma cell line HL-60.

RESULTSA specific 40 kDa beta 2GPI band was observed by ligand blotting in the case of smmc7721 cells. No such band was observed in SGC7901 or HL-60 cells. Fluorescence microscopy also revealed specific binding of FITC-beta 2GPI to smmc7721 cells, but neither to SGC7901 nor HL-60 cells. FACS analysis demonstrated that the binding rate of FITC-beta 2GPI to smmc7721 cells was significantly higher than these in SGC7901 and HL-60 cells (P < 0.01). The binding rate to smmc7721 cells did not increase with increasing amounts of FITC-beta 2GPI.

CONCLUSIONSThere is a specific beta 2GPI-binding protein on the membrane of hepatoma cells in cell line smmc7721 which as the beta 2GPI receptor may participate in HBV infection of hepatocytes.

Animals ; Carcinoma, Hepatocellular ; Cell Membrane ; metabolism ; Flow Cytometry ; Glycoproteins ; metabolism ; Hepatocytes ; metabolism ; Liver Neoplasms, Experimental ; metabolism ; Platelet Glycoprotein GPIb-IX Complex ; analysis ; Platelet Membrane Glycoproteins ; Tumor Cells, Cultured ; beta 2-Glycoprotein I